Mester T - Search Results

1

Teprotumumab for thyroid eye disease: early response is not required for benefit.

Ugradar S, Wang Y, Mester T, Kahaly GJ, Douglas RS. Ugradar S, et al. Among authors: mester t. Eye (Lond). 2022 Jul;36(7):1403-1408. doi: 10.1038/s41433-021-01539-5. Epub 2021 Jun 28. Eye (Lond). 2022. PMID: 34183792 Free PMC article.

2

Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.

Ugradar S, Shi L, Wang Y, Mester T, Yang H, Douglas RS. Ugradar S, et al. Among authors: mester t. Eye (Lond). 2021 Sep;35(9):2607-2612. doi: 10.1038/s41433-020-01297-w. Epub 2020 Nov 21. Eye (Lond). 2021. PMID: 33221815 Free PMC article.

3

Improvement of asymmetric thyroid eye disease with teprotumumab.

Ugradar S, Wang Y, Mester T, Kahaly GJ, Douglas R. Ugradar S, et al. Among authors: mester t. Br J Ophthalmol. 2022 Jun;106(6):755-759. doi: 10.1136/bjophthalmol-2020-318314. Epub 2021 Feb 12. Br J Ophthalmol. 2022. PMID: 33579690 Free PMC article. Clinical Trial.

4

TSH-Mediated TNFα Production in Human Fibrocytes Is Inhibited by Teprotumumab, an IGF-1R Antagonist.

Chen H, Shan SJ, Mester T, Wei YH, Douglas RS. Chen H, et al. Among authors: mester t. PLoS One. 2015 Jun 18;10(6):e0130322. doi: 10.1371/journal.pone.0130322. eCollection 2015. PLoS One. 2015. PMID: 26087256 Free PMC article.

5

Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.

Chen H, Mester T, Raychaudhuri N, Kauh CY, Gupta S, Smith TJ, Douglas RS. Chen H, et al. Among authors: mester t. J Clin Endocrinol Metab. 2014 Sep;99(9):E1635-40. doi: 10.1210/jc.2014-1580. Epub 2014 May 30. J Clin Endocrinol Metab. 2014. PMID: 24878056 Free PMC article.

6

Thyrotropin receptor and CD40 mediate interleukin-8 expression in fibrocytes: implications for thyroid-associated ophthalmopathy (an American Ophthalmological Society thesis).

Douglas RS, Mester T, Ginter A, Kim DS. Douglas RS, et al. Among authors: mester t. Trans Am Ophthalmol Soc. 2014;112:26-37. Trans Am Ophthalmol Soc. 2014. PMID: 25411513 Free PMC article.

7

Interleukin-6 production in CD40-engaged fibrocytes in thyroid-associated ophthalmopathy: involvement of Akt and NF-κB.

Gillespie EF, Raychaudhuri N, Papageorgiou KI, Atkins SJ, Lu Y, Charara LK, Mester T, Smith TJ, Douglas RS. Gillespie EF, et al. Among authors: mester t. Invest Ophthalmol Vis Sci. 2012 Nov 21;53(12):7746-53. doi: 10.1167/iovs.12-9861. Invest Ophthalmol Vis Sci. 2012. PMID: 23092922 Free PMC article.

8

Thyrotropin and CD40L Stimulate Interleukin-12 Expression in Fibrocytes: Implications for Pathogenesis of Thyroid-Associated Ophthalmopathy.

Wu T, Mester T, Gupta S, Sun F, Smith TJ, Douglas RS. Wu T, et al. Among authors: mester t. Thyroid. 2016 Dec;26(12):1768-1777. doi: 10.1089/thy.2016.0243. Epub 2016 Oct 18. Thyroid. 2016. PMID: 27612658 Free PMC article.

9

CD40 Expression in Fibrocytes Is Induced by TSH: Potential Synergistic Immune Activation.

Mester T, Raychaudhuri N, Gillespie EF, Chen H, Smith TJ, Douglas RS. Mester T, et al. PLoS One. 2016 Sep 15;11(9):e0162994. doi: 10.1371/journal.pone.0162994. eCollection 2016. PLoS One. 2016. PMID: 27631497 Free PMC article.

10

CD34- Orbital Fibroblasts From Patients With Thyroid-Associated Ophthalmopathy Modulate TNF-α Expression in CD34+ Fibroblasts and Fibrocytes.

Lu Y, Atkins SJ, Fernando R, Trierweiler A, Mester T, Grisolia ABD, Mou P, Novaes P, Smith TJ. Lu Y, et al. Among authors: mester t. Invest Ophthalmol Vis Sci. 2018 May 1;59(6):2615-2622. doi: 10.1167/iovs.18-23951. Invest Ophthalmol Vis Sci. 2018. PMID: 29847668 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42 results

Search Page

Filters